EGFR is an extensively studied biomarker in head and neck squamous cell carcinoma
(HNSCC). In this review, we discuss the prognostic and predictive role of EGFR in HNSCC …

Background: Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase
domain (TKD) are associated with response and resistance to targeted therapy. The EGFR …

Comprehensive genomic profiling is expected to revolutionize cancer therapy. In this
Prospective, we present the prevalence of mutations and copy-number alterations with …

Background Cetuximab, an anti-EGFR monoclonal antibody, is used to treat several
cancers. However, many patients who initially respond to cetuximab acquire resistance. To …

Head and neck squamous cell carcinoma (HNSCC) represent 95% of head and neck cancer
with an incidence of over half a million people globally. The prognosis for patients with …

Background PI3K pathway is the most frequently mutated pathway in head and neck
squamous cell carcinoma (HNSC), which plays a crucial role in tumorigenesis and …

Objectives To examine the impact of epidermal growth factor receptor (EGFR) expression
level on the efficacy of monoclonal antibodies against the EGFR. Methods In four human …

Рост частоты плоскоклеточного рака орофарингеальной области (ОФО) и
преобладание местнораспространенных форм опухоли у 60% с ранним …

Introduction Squamous carcinoma is the commonest malignancy of the head and neck
region. It is associated with high morbidity and mortality. Epidermal growth factor receptor …

Ionizing radiation has been shown to activate and interact with multiple growth factor
receptor pathways that can influence tumor response to therapy. Among these receptor …